A Single-center, Double-blind, Randomized, Placebo-controlled, Two-way Crossover Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

Trial Profile

A Single-center, Double-blind, Randomized, Placebo-controlled, Two-way Crossover Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Aprocitentan (Primary)
  • Indications Cardiovascular disorders; Hypertension
  • Focus Pharmacodynamics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 11 Jan 2017 Status changed from recruiting to completed.
    • 29 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
    • 29 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top